This is an optimized Investor Page for viewing on mobile devices, to view our entire Investor Relations site click here.
May 9, 2012
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
> Read More
May 2, 2012
Johnson & Johnson to Participate in 2012 Deutsche Bank Securities, Inc. 37th Annual Health Care Conference
> Read More
May 2, 2012
Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotech Co., Ltd.
> Read More
May 2, 2012
Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
> Read More
Apr 26, 2012
Johnson & Johnson Holds 2012 Annual Meeting of Shareholders
> Read More
Jul 17, 2012 at 8:30 AM
Johnson & Johnson Second Quarter 2012 Earnings Conference Call
Oct 16, 2012 at 8:30 AM
Johnson & Johnson Third Quarter 2012 Earnings Conference Call
Nov 1, 2012 at 8:30 AM
Johnson & Johnson Medical Devices & Diagnostics Business Review
© 1992-2008 JNJ Systems, Inc. All rights reserved.